Quick Answer
Indaptus Therapeutics, Inc. reported Operating Income of -$19.83 million for fiscal year 2025.
Indaptus Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$19.83M | -29.1% |
| 2024 | -$15.37M | +6.2% |
| 2023 | -$16.38M | -9.8% |
| 2022 | -$14.91M | -92.9% |
| 2021 | -$7.73M | -114.7% |
| 2020 | -$3.60M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.65M | +15.7% | +40.6% |
| June 30, 2025 | -$4.46M | -8.5% | +2.5% |
| March 31, 2025 | -$4.57M | -16.0% | -45.5% |
| September 30, 2024 | -$3.14M | +26.0% | +23.5% |
| June 30, 2024 | -$4.11M | -17.6% | -4.2% |
| March 31, 2024 | -$3.94M | +11.5% | +7.2% |
| September 30, 2023 | -$4.25M | -19.6% | -21.5% |
| June 30, 2023 | -$3.50M | +9.7% | +21.5% |
- Indaptus Therapeutics, Inc. showed a decrease of -29.1% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Indaptus Therapeutics, Inc.’s operating income has declined by 451.0% (from -$3.60 million to -$19.83 million).
- The most recent figure is from Indaptus Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: